Genmab AS Earnings

The next earnings date for Genmab AS is November 6, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Genmab AS Earnings

Report Date	Estimated Earnings Per Share
11/06/2025	$0.44

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Genmab AS Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
08/07/2025	After Market	$0.54	59.41%
04/30/2025	After Market	$0.31	34.12%
02/12/2025	After Market	$0.84	132.94%
11/06/2024	After Market	$0.29	-17.14%
08/08/2024	After Market	$0.31	-6.06%
05/02/2024	After Market	$0.29	107.14%
02/14/2024	After Market	$0.14	-96.49%
11/07/2023	After Market	$0.47	-85.03%
08/03/2023	After Market	$0.30	-86.24%
05/10/2023	After Market	$0.05	-92.31%
02/22/2023	After Market	$0.12	-96.19%
11/09/2022	After Market	$0.53	-67.88%
08/10/2022	After Market	$0.41	-73.55%
05/11/2022	After Market	$0.11	-87.91%
02/16/2022	After Market	$0.17	-96.79%
11/10/2021	After Market	$0.21	59.70%
08/11/2021	After Market	$0.08	10.65%
05/21/2021	---	$0.27	17.39%
02/23/2021	After Market	$0.14	-89.06%
11/11/2020	Before Market	$0.13	-86.87%
08/12/2020	After Market	$7.58	17.88%
05/06/2020	After Market	$0.30	3.45%
02/19/2020	After Market	$3.41	-0.58%
11/06/2019	After Market	$1.23	241.67%
08/20/2019	After Market	$0.20	-25.93%
05/08/2019	---	$0.02	---
02/19/2019	---	$0.20	---
11/14/2018	---	$0.04	---
08/08/2018	---	$0.07	---
05/08/2018	---	$0.05	---
02/21/2018	---	$0.21	---
11/08/2017	---	$-0.00	---
08/09/2017	---	$0.08	---
05/11/2017	---	$0.00	---
02/22/2017	---	$0.04	---
11/02/2016	---	$0.05	---
09/30/2016	---	$0.46	---
06/30/2016	---	$0.41	---
03/31/2016	---	$-0.03	---
12/31/2015	---	$0.95	---
09/30/2015	---	$0.34	---
06/30/2015	---	$0.04	---
03/31/2015	---	$0.52	---
12/31/2014	---	$0.19	---
09/30/2014	---	$0.47	---
06/30/2014	---	$-0.08	---
03/31/2014	---	$0.32	---
12/31/2013	---	$0.21	---
09/30/2013	---	$0.02	---
06/30/2013	---	$-0.09	---
03/31/2013	---	$0.10	---
12/31/2012	---	$-0.06	---
09/30/2012	---	$-0.17	---
06/30/2012	---	$0.03	---
03/31/2012	---	$-0.25	---
12/31/2011	---	$-0.13	---
09/30/2011	---	$-0.03	---
06/30/2011	---	$-0.31	---
03/31/2011	---	$-0.43	---
12/31/2010	---	$-0.31	---
08/17/2010	---	$-0.03	---
05/11/2010	---	$-0.05	---
03/03/2010	---	$-0.16	---
11/10/2009	---	$-0.04	---
08/18/2009	---	$-0.05	---

More About Genmab AS

Website

https://www.genmab.com

Country

USA

Full Time Employees

2,639

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

“Genmab AS Earnings” Can Refer to the Genmab AS Earnings Date

Some people say “Genmab AS earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Genmab AS position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Genmab AS Stock on the Earnings Date

If you own Genmab AS stock (GMAB) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Genmab AS might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Genmab AS shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Genmab AS Earnings

You can contact us any time if you would like to ask questions about Genmab AS earnings or anything else related to the stock market.